Open AccessS809 A Higher Induction Dosing Regimen of Adalimumab Does Not Enhance Modulation of Downstream Blood Molecular Markers in Patients With Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis
Author(s) -
Marc Ferrante,
Valerie Pivorunas,
J. W. Butler,
Naim Al Mahi,
Nael M. Mostafa,
Melanie C. Ruzek,
James I. Fann,
Hui Feng,
Xiaohong Cao,
Nizar Smaoui,
J. Wade Davis,
Jasmina Kalabic,
Alexandra Song,
Heath Guay,
Florian Rieder,
Julián Panés,
Jean–Frédéric Colombel
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776768.33716.45
Subject(s) - medicine , ulcerative colitis , adalimumab , gastroenterology , regimen , clinical endpoint , biomarker , crohn's disease , population , randomized controlled trial , disease , biochemistry , chemistry , environmental health